Fate therapeutics to participate at upcoming september investor conferences

San diego, sept. 02, 2022 (globe newswire) -- fate therapeutics, inc. (the “company” or “fate therapeutics”) (nasdaq: fate), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the company will participate in the following upcoming investor conferences:
FATE Ratings Summary
FATE Quant Ranking